Navigation Links
Operating without interrupting warfarin reduces risk of bleeding after cardiac device surgery
Date:5/10/2013

DENVER, May 9, 2013 A new Canadian study shows that operating without interrupting warfarin treatment at the time of cardiac device surgery is safe and markedly reduces the incidence of clinically significant hematomas compared to the current standard of care. The new findings were released today at Heart Rhythm 2013, the Heart Rhythm Society's 34th Annual Scientific Sessions, and will be published online today in The New England Journal of Medicine (NEJM).

At least a quarter of patients that require pacemaker or implantable defibrillator surgery are taking warfarin to reduce the risk of a stroke. Current guidelines recommend bridging many of these patients to heparin treatment and stopping anticoagulation therapy in the days leading up to surgery which can put a patient at risk of a stroke. The Bruise Control trial is the largest randomized clinical trial to compare continuing warfarin to temporary cessation with heparin bridging in patients before and after device surgery.

"We hope that Bruise Control will change how we are treating patients around the world," said lead author David Birnie, MD, Director of the Arrhythmia Service at the University of Ottawa Heart Institute, Canada. "Our study conclusively shows that treating patients with a high risk of stroke with continued warfarin instead of heparin bridging will improve patient outcomes, decrease complications and reduce hospitalization."

Bruise Control randomized 681 patients at 17 Canadian and 1 Brazilian center with a less than 5 percent annual risk of thrombo-embolic events. One group received continued warfarin, while the other patients were bridged to therapeutic doses of either intravenous heparin or subcutaneous low-molecular-weight heparin starting three days before the procedure and resuming 24 hours after surgery. Patients were evaluated after surgery and the study found that clinically significant hematomas were 80 percent less frequent in patients t
'/>"/>

Contact: Vincent Lamontagne
vlamontagne@ottawaheart.ca
613-761-4427
University of Ottawa Heart Institute
Source:Eurekalert

Page: 1 2

Related biology technology :

1. Danai Brooks Joins Dyadic International as Chief Operating Officer
2. Regeneron Reports First Quarter 2013 Financial and Operating Results
3. AFcell Medical Hires Chief Operating Officer
4. - Unigene Secures Financing to Extend Operating Runway in Conjunction with Strategic Reorganization -
5. Cempra, Inc. Reports Fourth Quarter and Full Year 2012 Financial and Operating Results
6. ABIA Hires Biomedical Executive, Serial Entrepreneur as Chief Operating Officer
7. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
8. Millions of DNA switches that power human genomes operating system are discovered
9. Preliminary Figures for 2011: Sartorius Grows at Double-Digit Rates and Boosts Operating Earnings by More Than 30%
10. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
11. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)...  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... announced that it will be presenting at CALBIO 2015 ... nd at 3pm PST. Patrick Lucy, chief business officer ... current state of the biosimilar industry landscape entitled ... For more information on CALBIO 2015 and The ...
(Date:2/27/2015)... CA (PRWEB) February 27, 2015 Cytokinetics, ... forces on February 28 with patients and health care ... awareness for Rare Disease Day®. Rare Disease Day ... and calling attention to the special challenges faced by ... them. , “Cytokinetics is proud to stand alongside patients ...
(Date:2/27/2015)... , Feb. 27, 2015   PureTech , a ... and commercializing disruptive products and technologies in the healthcare ... , former CEO and Member of the Board of ... "It,s has been a pleasure to know ... that we will be working together more closely now," ...
(Date:2/26/2015)... 26, 2015 On behalf of biotech client ... Wilentz, Goldman & Spitzer, P.A. (Wilentz) secured a ... Genewiz Inc. in excess of $10 million. The jury ... secrets, and that it improperly hired one or more ... motions for judgment notwithstanding the verdict, a new trial, ...
Breaking Biology Technology:Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... and VANCOUVER, Feb. 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ... survival rate from a Phase 1/2 clinical trial of ... of advanced non-small cell lung cancer (NSCLC). At two ... first-line chemotherapy were alive. OncoGenex has previously reported a ...
... introduction to the benefits of Shape Memory Alloys. The Kit is a ... a comprehensive manual, and easy to follow demonstrations on the morphing abilities ... ... -- Imagine a future where the only tool in an auto body ...
... HUNTINGTON BEACH, California and AMSTERDAM, February 4 ... diagnostics, today announced that,its signature breast cancer ... of,care for all eligible early stage breast ... Leeuwenhoek Hospital (NKI-AVL). The NKI-AVL,believes MammaPrint provides ...
Cached Biology Technology:OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer 2OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer 3OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer 4OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer 5Re-Shaping the Future with Shape Memory Alloys - SMA Starter Kit 2Re-Shaping the Future with Shape Memory Alloys - SMA Starter Kit 3Agendia's Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL 2
(Date:2/5/2015)... TRIANGLE PARK, North Carolina , 5. ... sein 35. Jahr als spezialisiertes Logistikunternehmen und ... Position als einzige klinische Logistikfirma (Clinical Logistics ... Die Kernbotschaft der neuen Kampagne lautet ... und Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... SAN FRANCISCO , January 28, 2015 ... Camera Market Analysis, Size And Segment Forecasts To 2020 ... The global IR camera market is expected to reach ... study by Grand View Research, Inc. IR cameras help ... injuries, and are expected to witness surging demand in ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced ... Overview" report to their offering. , ... an individual is who she/he is claiming to be, and ... person,s unique physical characteristics, such as fingerprint, hand or palm ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... so indelibly that their children are affected. History ... starvation, whose children experience altered physiology. Now ... University have found an instance of animals passing ... to their offspring. That information comes not through ...
... mapping how proteins interact with each other, developed at ... the design of new drugs for diseases such as ... acids, the Salk scientists determine the detailed molecular structure ... that turns it on. The switch--corticotrophin releasing factor type ...
... 29 November 2013 The American Association for the Advancement ... Science Policy Programme at EMBO, to its 2013 class of ... upon AAAS members by their peers and acknowledges contributions that ... been recognized by AAAS for her work looking at the ...
Cached Biology News:Mice can inherit learned sensitivity to a smell 2Mice can inherit learned sensitivity to a smell 3Salk scientists crack riddle of important drug target 2Salk scientists crack riddle of important drug target 3
... The electrophoretic mobility shift assay (EMSA) ... interactions. Often referred to as gel shift ... on the principle that when subjected to ... a DNA-protein complex. The Pierce LightShift Chemiluminescent ...
... Lab Quantas unique combination of Coulter ... resolution capabilities and accurate cell counting. ... wavelengths, including UV, allowing flexible fluorochrome ... applications typically only achievable with larger, ...
... Genome-pULSe Kit delivers a novel procedure for ... labeling of whole genome DNA from small ... provide a quick and highly reproducible amplification ... consists of a REPLI-g Mini Kit module ...
... using PULSin may be superior to transfection ... traditional transfection, with PULSin you can study ... time course of proteins in cells. Likewise, ... information than traditional RNA interference experiments. ...
Biology Products: